Navigation Links
Novo Nordisk Applauds Adoption of World Diabetes Day Resolutions by U.S. Congress
Date:11/21/2007

First U.S. resolution to shine spotlight on crisis affecting 246 million

people worldwide

PRINCETON, N.J., Nov. 21 /PRNewswire-FirstCall/ -- On the eve of World Diabetes Day, leaders in the U.S. House of Representatives passed House Concurrent Resolution 211 supporting the goals and ideals of World Diabetes Day, which is recognized annually on November 14. Then, the next day, on World Diabetes Day itself, the U.S. Senate followed suit, passing Senate Resolution 382. More than 20 million Americans have diabetes, and that number is expected to double by 2025.

Passage of the U.S. resolution marks the first time Congress has officially supported World Diabetes Day since it was established in 1991 by the World Health Organization and the International Diabetes Federation, of which Novo Nordisk is a member. It represents an important milestone in a busy month of activities taking place as part of National Diabetes Month.

As the lead industry supporter of the resolution, Novo Nordisk and its National Changing Diabetes(R) Program have worked closely with many of the resolution sponsors, including Reps. Donald Payne (D-N.J.) and Donald Manzullo (R-Ill.) and Sens. Debbie Stabenow (D-Mich.), Pete Domenici (R-N.M.), Frank Lautenberg (D-N.J.) and Norman Coleman (R-Minn.) to help focus attention on diabetes and make the disease a top national health care priority.

"With over 80 years in diabetes care, Novo Nordisk commends the leadership and commitment of Representatives Payne and Manzullo and Senators Stabenow, Domenici, Lautenberg and Coleman, and the entire Congress. The attention and urgency these resolutions will bring to diabetes prevention and treatment efforts in the United States is a positive step forward in our shared passion of changing diabetes," said Martin Soeters, president of Novo Nordisk Inc.

The United Nations General Assembly passed a World Diabetes Day Resolution on December 20, 2006, recognizing diabetes as a chronic, debilitating and costly disease that is associated with major complications and poses severe risks for families, countries and the global community.

In addition to supporting diabetes awareness on a national level, Novo Nordisk is active at the state level, working closely with elected officials and diabetes leaders to introduce proclamations in support of World Diabetes Day in Florida, Georgia, Mississippi, New Jersey and West Virginia.

For more information on Novo Nordisk and the National Changing Diabetes(R) Program visit novonordisk-us.com and ncdp.com.

About Novo Nordisk

Novo Nordisk is a health care company with an 84-year history of innovation and achievement in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness, and social responsibility to employees and customers. With headquarters in Denmark, Novo Nordisk employs more than 25,800 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For global information, visit novonordisk.com; for United States information, visit novonordisk-us.com. Further information:


'/>"/>
SOURCE Novo Nordisk
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
2. Novo Nordisk Increased Operating Profit by 11% in the First Nine Months of 2007 Based on a 9% Sales Increase and an Improved Gross Margin
3. Novo Nordisk Inc. Announces Exclusive Agreement With Sciele Pharma, Inc. to Market Prandin(R)
4. FRC Applauds New Ballot Initiative for Cures Without Cloning
5. YM Biosciences announces adoption of renewed Shareholders Rights Plan
6. Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
7. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
8. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
9. Safety Profile of TAXUS(R) Liberte(TM) Stent System Highlighted in Worlds Largest Stent Registry
10. CeloNova BioSciences Announces Worlds First Line of Fully Color-Coded Embolic Particles at CIRSE: Embozene(TM) Color-Advanced Microspheres
11. Stereotaxis Niobe System Used to Perform More Than 10,000 Procedures Worldwide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Global demand for ... percent through 2020 to $7.2 billion.  This market ... beverages, cleaning products, biofuel production, animal feed, and ... diagnostics, and biocatalysts). Food and beverages will remain ... by increasing consumption of products containing enzymes in ...
(Date:6/27/2016)... ... 2016 , ... Newly created 4Sight Medical Solutions ... healthcare market. The company's primary focus is on new product introductions, to include ... are necessary to help companies efficiently bring their products to market. , The ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
Breaking Biology Technology:
(Date:6/20/2016)... DALLAS , June 20, 2016 ... criminal justice technology solutions for public safety, investigation, ... by the prisons involved, it has secured the ... Corrections (DOC) facilities for Managed Access Systems (MAS) ... (4) additional facilities to be installed by October, ...
(Date:6/9/2016)... attendance control systems is proud to announce the introduction of fingerprint attendance control software, ... employees are actually signing in, and to even control the opening of doors. ... ... ... Photo - http://photos.prnewswire.com/prnh/20160609/377487 ...
(Date:6/3/2016)... 2016 Das DOTM ... Nepal hat ein 44 Millionen ... Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an ... und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale ... teilgenommen, aber Decatur wurde als konformste und ...
Breaking Biology News(10 mins):